Gut Bacteria Pair Linked to Intestinal Inflammation

Researchers identify two bacterial species that activate immune cells and drive inflammation, and five compounds that inhibit them.

Updated on Nov. 13, 2026 in Life Sciences

Isometric editorial illustration of clustered bacterial cells on a flat glass slide, one cluster partly cut away in a pale wedge, in deep teal and cream.
Researchers identified Sarcina perfringens and Hathewaya massiliensis as gut bacteria that trigger intestinal inflammation, and five compounds that selectively inhibit them. AI Illustration. Upload story photo >

Live Poll

Do you trust scientists to develop safe new treatments for chronic illnesses?

Researchers identified Sarcina perfringens and Hathewaya massiliensis as gut bacteria capable of triggering or worsening intestinal inflammation, both of which activate cells of the innate immune system. The study, published in the journal Gut, also identified five compounds that selectively inhibit the growth of these two species.

Why it matters

The gut microbiome is often altered in people with inflammatory bowel disease, but it has frequently been unclear which bacteria actually contribute to inflammation. Identifying specific bacterial triggers could allow treatments to target them directly rather than broadly disrupting the gut community.

The evidence comes from screening 1,518 previously approved compounds and comparing stool samples from patients before and after antibiotic or fecal microbiota treatment, with Sarcina perfringens elevated in roughly 25 to 30 percent of people with inflammatory bowel disease and Hathewaya massiliensis in about five percent. Whether these findings translate to safe and effective human treatment remains unknown.

The players

Gut

Gut is a peer-reviewed medical journal published by BMJ that focuses on gastroenterology and hepatology research.

The details

Researchers compared stool samples collected from patients before and after treatment with antibiotics or fecal microbiota transplantation, then transferred gut microorganisms into germ-free mice to study their effects on inflammation. In a mouse model, oxolinic acid reduced Sarcina perfringens-promoted inflammation with efficacy comparable to metronidazole, while having only a minor impact on the remaining bacterial community unlike metronidazole.

Timeline

  1. The study was published online in the journal Gut on November 11, 2026.

Life Sciences Landscape

The discovery builds on decades of work using antibiotics and fecal microbiota transplantation to reshape gut communities in inflammatory bowel disease. It shifts the approach from broad microbiome disruption toward targeting individual bacterial species that drive inflammation.

If targeted bacterial treatments are developed, they could complement current inflammatory bowel disease therapies by addressing specific triggers. Patients and clinicians would not see changes to treatment options until human safety and efficacy are established.

The takeaway

Targeting specific bacteria rather than the whole gut community may one day offer more precise options for managing inflammatory bowel disease. Human safety and effectiveness still need to be confirmed before any such approach is used in care.

Further reading

Explore more research on the Life Sciences section for related studies on the human microbiome and disease.

More information

Read the full Original Gut journal study publication in the journal Gut.

Live Poll

Do you trust scientists to develop safe new treatments for chronic illnesses?